These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16820069)

  • 1. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies.
    Barton SE; Engelhard P; Conant M
    Int J STD AIDS; 2006 Jul; 17(7):429-35. PubMed ID: 16820069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.
    Levy RM; Redbord KP; Hanke CW
    J Am Acad Dermatol; 2008 Dec; 59(6):923-33. PubMed ID: 19022099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
    Hanke CW; Redbord KP
    J Drugs Dermatol; 2007 Feb; 6(2):123-8. PubMed ID: 17373169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
    AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly-L-lactic acid.
    Perry CM
    Am J Clin Dermatol; 2004; 5(5):361-6; discussion 367-8. PubMed ID: 15554738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.
    Burgess C
    J Drugs Dermatol; 2011 Sep; 10(9):1001-6. PubMed ID: 22052268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly-L-lactic acid for facial lipoatrophy in HIV.
    El-Beyrouty C; Huang V; Darnold CJ; Clay PG
    Ann Pharmacother; 2006 Sep; 40(9):1602-6. PubMed ID: 16912248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
    Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B
    Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly-L-lactic acid as a facial filler.
    Sterling JB; Hanke CW
    Skin Therapy Lett; 2005 Jun; 10(5):9-11. PubMed ID: 15986083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
    van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
    Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.
    Carey DL; Baker D; Rogers GD; Petoumenos K; Chuah J; Easey N; Machon K; Cooper DA; Emery S; Carr A;
    J Acquir Immune Defic Syndr; 2007 Dec; 46(5):581-9. PubMed ID: 18193500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
    Carey D; Baker D; Petoumenos K; Chuah J; Rogers GD; Watson J; Cooper DA; Emery S; Carr A;
    HIV Med; 2009 Mar; 10(3):163-72. PubMed ID: 19245538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.
    Duracinsky M; Leclercq P; Herrmann S; Christen MO; Dolivo M; Goujard C; Chassany O
    BMC Infect Dis; 2014 Sep; 14():474. PubMed ID: 25178390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of facial lipoatrophy in HIV-infected patients.
    Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-L-lactic acid: a new dimension in soft tissue augmentation.
    Rotunda AM; Narins RS
    Dermatol Ther; 2006; 19(3):151-8. PubMed ID: 16784514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.